Related Experiment Videos
2,3-diaminopyridine bradykinin B1 receptor antagonists
Scott D Kuduk1, Christina Ng, Dong-Mei Feng
1Department of Medicinal Chemistry, Merck Research Laboratories, PO Box 4, West Point, Pennsylvania 19486, USA. scott_d_kuduk@merck.com
Journal of Medicinal Chemistry
|December 14, 2004
Abstract:
Bradykinin B1 receptor antagonists embody a potentially novel approach for the treatment of chronic pain and inflammation. A series of 2,3-diaminopyridine B1 antagonists was optimized to have sub-nanomolar affinity and good pharmacokinetic properties. Lead compounds were shown to exhibit good efficacy in rabbit in vivo models of pain and inflammation.